A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this ...
U.S. Fast Track designation of ART6043 underpinned by promising clinical data to date and high unmet need in gBRCA-mutated HER2-negative breast ...
HIGHLIGHTSAmplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US ...
There is much to be said for temptation in two dimensions. A menu, stuck against the window of a restaurant or framed on the wall outside, calls out to our salivary glands and draws us over the ...
Waverley Pharma Inc. has discovered substituted (3-hydroquinazolin-4-one) derivatives acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors and thus potentially useful for the treatment ...
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through ...
RESEARCH TRIANGLE PARK, N.C., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) (Nasdaq: BCRX) today announced that the company will present nine abstracts from its hereditary ...
BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results